FLT3/ITD-mutated AML
Sorafenib and Plerixafor Plus G-CSF Mobilizes Leukemia Cells, Leads to ‘Encouraging Rates of Response’ in FLT3/ITD-Mutated AML
Leah SherwoodAcute Myeloid Leukemia | February 2, 2023
A chemotherapy-free treatment with sorafenib and plerixafor plus G-CSF mobilized leukemia cells.
Read More
Triplet Combo Quizartinib, Decitabine, and Venetoclax Active in Patients with FLT3/ITD-Mutated AML
Leah SherwoodAcute Myeloid Leukemia | February 2, 2023
Of 23 patients, three achieved complete remission and 15 achieved complete remission with incomplete hematological recovery.
Read More
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Editorial Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |